Please use this identifier to cite or link to this item:
Title: Targeting pro-tumorigenic signaling pathways in hematolymphoid malignancies
Authors: Kizhakeyil Atish
Keywords: Science::Medicine
Issue Date: 2020
Publisher: Nanyang Technological University
Source: Kizhakeyil Atish. (2020). Targeting pro-tumorigenic signaling pathways in hematolymphoid malignancies. Doctoral thesis, Nanyang Technological University, Singapore.
Abstract: Hematolymphoid malignancies constitute diverse forms of cancers derived from hematopoietic and lymphoid tissues. Determining molecular alterations driving resistance to commonly used chemotherapies and defining disease mechanisms are of considerable relevance for understanding the pathogenesis of hematolymphoid malignancies. Here, using RNA-seq and proteomics analyses we identified several pro-tumorigenic signaling, including STAT3 and ERK pathways, to be involved in drug resistance in hematolymphoid malignancies. We demonstrated that the X-linked DDX3X is a crucial determinant in NHL aggressiveness. We established that STAT3 activation upregulates PD-L1 expression in cells of hematolymphoid malignancies. We optimized the “GapmeR” technology and developed a novel gene silencer “epAON” that were effective in knocking down STAT3 in cells of hematolymphoid malignancies and successful in inducing apoptosis in these cells. epAON molecules can be exploited for therapeutic applications. Overall, the data presented in this thesis greatly enhances the understanding of fundamental intracellular mechanisms involved in hematolymphoid malignancies.
DOI: 10.32657/10356/142248
Rights: This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Theses

Files in This Item:
File Description SizeFormat 
Doctoral Thesis.pdf7.05 MBAdobe PDFThumbnail

Page view(s)

Updated on Feb 24, 2021


Updated on Feb 24, 2021

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.